AR050615A1 - Composiciones farmaceuticas para la administracion oral - Google Patents

Composiciones farmaceuticas para la administracion oral

Info

Publication number
AR050615A1
AR050615A1 ARP050103558A ARP050103558A AR050615A1 AR 050615 A1 AR050615 A1 AR 050615A1 AR P050103558 A ARP050103558 A AR P050103558A AR P050103558 A ARP050103558 A AR P050103558A AR 050615 A1 AR050615 A1 AR 050615A1
Authority
AR
Argentina
Prior art keywords
granules
therapeutic compound
moisture sensitive
mixture
fusion
Prior art date
Application number
ARP050103558A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050615(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR050615A1 publication Critical patent/AR050615A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formas de dosis orales solidas incluyen gránulos de fusion de un compuesto terapéutico sensible a la humedad y un componente de fusion hidrofobico. Los gránulos de fusion protegen mejor al compuesto terapéutico de la degradacion hidrolítica. Tales formas de dosis orales solidas también poseen características de liberacion inmedita más que asociadas con productos de fármacos de liberacion extendida o liberacion controlada. Reivindicacion 8: La composicion farmacéutica de acuerdo con la reivindicacion 1, en donde dicho compuesto terapéutico sensible a la humedad es una 2-cianopirrolidina N-(glicilo substituida) o una sal farmacéuticamente aceptable del mismo. Reivindicacion 9: La composicion farmacéutica de acuerdo con la reivindicacion 8, en donde dicha 2-cianopirrolidina N-(glicilo substituida) tiene la formula (1). Reivindicacion 12: Un procedimiento para hacer gránulos que comprende los pasos de: (a) formar una mezcla de un compuesto terapéutico sensible a la humedad con al menos un componente de fusion hidrofobico; (b) calentar dicha mezcla a una temperatura substancialmente cerca del rango de fusion de dicho componente de fusion hidrofobico; (c) granular la mezcla bajo esfuerzo cortante para formar dichos gránulos; y (d) enfriar dichos gránulos a temperatura ambiente.
ARP050103558A 2004-08-27 2005-08-25 Composiciones farmaceuticas para la administracion oral AR050615A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60532704P 2004-08-27 2004-08-27
US61682804P 2004-10-07 2004-10-07

Publications (1)

Publication Number Publication Date
AR050615A1 true AR050615A1 (es) 2006-11-08

Family

ID=35447883

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103558A AR050615A1 (es) 2004-08-27 2005-08-25 Composiciones farmaceuticas para la administracion oral

Country Status (21)

Country Link
US (1) US20080050443A1 (es)
EP (2) EP3087975A1 (es)
JP (1) JP5147399B2 (es)
KR (8) KR101613775B1 (es)
CN (1) CN101010068B (es)
AR (1) AR050615A1 (es)
AU (1) AU2005276583B2 (es)
BR (1) BRPI0514682B8 (es)
CA (1) CA2575499A1 (es)
DK (1) DK1786401T3 (es)
ES (1) ES2647671T3 (es)
HU (1) HUE034653T2 (es)
MX (1) MX2007002253A (es)
MY (1) MY144297A (es)
PE (1) PE20060652A1 (es)
PL (1) PL1786401T3 (es)
PT (1) PT1786401T (es)
RU (1) RU2383332C2 (es)
SI (1) SI1786401T1 (es)
TW (1) TWI402082B (es)
WO (1) WO2006021455A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2684325T5 (es) 2004-01-20 2024-06-10 Novartis Ag Formulación y proceso de compresión directa
CA2554493C (en) 2004-02-05 2012-06-26 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
PE20060652A1 (es) 2004-08-27 2006-08-11 Novartis Ag Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion
JP5101489B2 (ja) 2006-03-08 2012-12-19 杏林製薬株式会社 アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体
WO2007128801A1 (en) * 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
ATE550319T1 (de) 2007-03-22 2012-04-15 Kyorin Seiyaku Kk Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats
DE102008020701A1 (de) * 2008-04-24 2009-10-29 Bayer Technology Services Gmbh Formulierung mit reduzierter Hygroskopizität
CA2732984A1 (en) 2008-08-07 2010-02-11 Kyorin Pharmaceutical Co., Ltd. Process for production of bicyclo[2.2.2]octylamine derivative
KR20110044780A (ko) * 2008-08-14 2011-04-29 교린 세이야꾸 가부시키 가이샤 안정화된 의약 조성물
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
CN102438617A (zh) 2009-03-27 2012-05-02 杏林制药株式会社 含有碱性添加剂的基质型缓释制剂
JP2011057586A (ja) * 2009-09-08 2011-03-24 Kyorin Pharmaceutical Co Ltd pH非依存性マトリックス型徐放性製剤
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
US8989577B2 (en) 2012-06-21 2015-03-24 Qualcomm Incorporated Methods and systems for implementing time-division duplexing in the physical layer
US9071358B2 (en) 2012-06-21 2015-06-30 Qualcomm Incrorporated Repeater fiber-coax units
US9363017B2 (en) 2012-07-06 2016-06-07 Qualcomm Incorporated Methods and systems of specifying coaxial resource allocation across a MAC/PHY interface
JP6283316B2 (ja) * 2012-10-26 2018-02-21 株式会社三和化学研究所 アナグリプチン含有固形製剤
US10369108B2 (en) * 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
CN104274408A (zh) * 2013-07-10 2015-01-14 北京科信必成医药科技发展有限公司 一种熔融包衣的速释药物微粒及其制备方法
WO2015195990A1 (en) * 2014-06-20 2015-12-23 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
ES2946233T3 (es) 2016-09-16 2023-07-14 Galenicum Health S L U Composiciones farmacéuticas de vildagliptina

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
DK0654263T3 (da) 1993-11-23 2002-04-29 Euro Celtique Sa Fremgangsmåde til fremstilling af et præparat med langvarig frigivelse
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US20020142037A1 (en) * 1996-10-01 2002-10-03 Nabil Farah Process for the manufacture of a pharmaceutical composition with modified release of active principle comprising a matrix
AU4721897A (en) 1996-10-25 1998-05-22 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
JP2002522354A (ja) * 1997-09-19 2002-07-23 シャイア ラボラトリーズ,インコーポレイテッド 固溶体ビードレット
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
MXPA03006918A (es) 2001-02-02 2004-05-24 Takeda Chemical Industries Ltd Compuestos heterociclicos fusionados.
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
EP1537880A4 (en) * 2002-09-11 2009-07-01 Takeda Pharmaceutical PREPARATION FOR PROLONGED RELEASE
WO2004037169A2 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1553937B1 (en) 2002-10-23 2010-06-02 Bristol-Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase iv
PE20060652A1 (es) 2004-08-27 2006-08-11 Novartis Ag Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion

Also Published As

Publication number Publication date
HUE034653T2 (hu) 2018-02-28
EP3087975A1 (en) 2016-11-02
AU2005276583A1 (en) 2006-03-02
KR20190006612A (ko) 2019-01-18
KR20160136465A (ko) 2016-11-29
KR20160017123A (ko) 2016-02-15
CA2575499A1 (en) 2006-03-02
MX2007002253A (es) 2007-04-20
PL1786401T3 (pl) 2018-01-31
KR20130043697A (ko) 2013-04-30
JP2008510764A (ja) 2008-04-10
EP1786401A1 (en) 2007-05-23
KR20200087870A (ko) 2020-07-21
EP1786401B1 (en) 2017-08-16
ES2647671T3 (es) 2017-12-26
AU2005276583B2 (en) 2009-12-03
RU2007110953A (ru) 2008-10-10
TW200613005A (en) 2006-05-01
MY144297A (en) 2011-08-29
US20080050443A1 (en) 2008-02-28
KR101613775B1 (ko) 2016-04-19
RU2383332C2 (ru) 2010-03-10
CN101010068B (zh) 2013-05-22
TWI402082B (zh) 2013-07-21
BRPI0514682A (pt) 2008-06-17
KR20070049646A (ko) 2007-05-11
CN101010068A (zh) 2007-08-01
KR20170103039A (ko) 2017-09-12
PT1786401T (pt) 2017-11-22
BRPI0514682B1 (pt) 2019-06-04
DK1786401T3 (da) 2017-11-27
WO2006021455A1 (en) 2006-03-02
SI1786401T1 (sl) 2017-12-29
KR20220061249A (ko) 2022-05-12
BRPI0514682B8 (pt) 2021-05-25
PE20060652A1 (es) 2006-08-11
JP5147399B2 (ja) 2013-02-20

Similar Documents

Publication Publication Date Title
AR050615A1 (es) Composiciones farmaceuticas para la administracion oral
MX2022014458A (es) Derivados de triazina que tienen actividad inhibidora de la replicacion del virus y composicion farmaceutica que constituye el mismo.
ES2593582T3 (es) Formulación de comprimido recubierto y método
ES2606043T3 (es) Derivados de biarilo como moduladores de nAChR
AR020727A1 (es) Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
HRP20230052T1 (hr) Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
CA2601955A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
HRP20171793T1 (hr) Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata
EA200901277A1 (ru) Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина
AR044856A1 (es) Acidos biariloximetilarenocarboxilicos; procedimientos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
CN110664816A (zh) Seca抑制剂以及其制备和使用方法
SA112330689B1 (ar) صيغة كبسولات تشتمل على مونتليوكاست وليڤوستيريزين
ECSP088457A (es) Compuestos de benzamida útiles como inhibidores de la histona deacetilasa
NO20084065L (no) Hurtig frigivelses paracetamol tabletter
CO5640071A2 (es) Composiciones farmaceuticas de atorvastatina
EA201171109A1 (ru) Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия
EA200901146A1 (ru) Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли
JP6168673B2 (ja) アリールアルキルアミン化合物含有医薬組成物
CA3155805A1 (en) Phosphonium ion channel blockers and methods for use
FI3769765T3 (fi) Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus
ES2235383T3 (es) Beta-alaninas sustituidas.
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
ES2211373T1 (es) Nuevas formas cristalinas de oxcarbazepina y procedimientos para su preparacion.
HRP20050831A2 (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
CL2004000779A1 (es) Compuestos derivados de 3-azabiciclo [3.2.1]octano, composicion farmaceutica, procedimiento de preparacion, util para preparar medicamentos para tratar sindrome de intestino irritable, estrenimiento, nauseas, vomitos, disfuncion sexual, alzheimer, en

Legal Events

Date Code Title Description
FC Refusal